Effect of modern, high‑quality prostate intensity‑modulated radiation therapy on outcome: Evidence from a community radiation oncology program
| Autor: | Shankar Taramangalam, Edward Loizides, Aaron J. Woodall, Andrew T. Wong, Jonathan Timmins, Jeffrey Pettit, Amanda Zucker, Johnny Kao |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty endocrine system diseases medicine.medical_treatment Urology Prostate cancer Prostate Internal medicine otorhinolaryngologic diseases Medicine Dosimetry neoplasms medicine.diagnostic_test business.industry Genitourinary system Cancer Magnetic resonance imaging Articles medicine.disease Radiation therapy stomatognathic diseases medicine.anatomical_structure Toxicity business therapeutics |
| Zdroj: | Molecular and Clinical Oncology. |
| ISSN: | 2049-9469 2049-9450 |
| DOI: | 10.3892/mco.2017.1290 |
| Popis: | Radiation technique for prostate cancer has continuously evolved over the past several decades. The aim of the present study was to describe the effects of implementing modern prostate intensity-modulated radiation therapy (M-IMRT) on dosimetry and outcome. Between January 2010 and April 2012, 48 consecutive patients were treated with conventional prostate IMRT (C-IMRT) to a dose of 81 Gy. Between May 2012 and April 2015, 50 consecutive patients were treated with M-IMRT to the entire prostate to a dose of 75.6–79.2 Gy, while using prostate magnetic resonance imaging fusion, dose-volume constraints prioritizing normal tissue avoidance above planning target volume coverage, and boosting any dominant intraprostatic masses to 79.2–81 Gy. Rectal Dmax, V75, V60, V65 and V50, bladder Dmax, V75, V70 and V65, and acute and late toxicities were compared between the C-IMRT and M-IMRT groups. The median follow-up for the C-IMRT and M-IMRT groups was 61 vs. 26 months, respectively (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|